| P447 | A case of checkpoint inhibitor-induced celiac disease | Dana Alsaadi; Neil J. Shah, MD; Aline Charabaty, MD; Michael Atkins, MD; | Autoimmunity; Checkpoint blockade; Immune toxicity; Inflammation |
| P448 | Blockade of EphB4-ephrin-B2 interaction remodels the tumor immune microenvironment in head and neck cancers | Sana Karam, MD, PhD; Shilpa Bhatia | Monocyte/Macrophage; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment |
| P449 | Improving PDAC outcomes through targeting immune populations and fibrosis by EphB4-ephrinB2 or Treg inhibition combined with radiation | Sana Karam, MD, PhD | Radiotherapy; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment |
| P450 | The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models | Luis A. Carvajal, PhD; Narayana Narasimhan, PhD; Jian-Guo Ren, PhD; Solimar Santiago, M.S; Manoj Samant, PhD; David Sutton, PhD; Vincent Guerlavais, PhD; D. Allen Annis, PhD; Manuel Aivado, MD/PhD; | Checkpoint blockade; Coinhibition; Immune suppression; Immune tolerance; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P451 | Gal9/Tim-3 expression level is higher in patient with failed chemotherapy in AML | Justin P. Kline, MDPAOLA DAMA, PhD; Hongtao Liu, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Immune toxicity; Leukemia/Lymphoma; Targeted therapy |
| P452 | Cisplatin treatment induces anti-tumor immune response in NSCLC by activation of the innate immune response pathway | CARMINIA M. DELLA CORTE, MD; Triparna Sen, PhD; Lixia Diao; Kavya Ramkumar; Carl M. Gay; Pan Tong; You-Hong Fan; Robert J. Cardnell; Don Gibbons, MD; John V. Heymach; Jing Wang; Lauren A. Byers, MD | Bioinformatics; Biomarkers; Chemotherapy; Gene expression; Proteomics |
| P453 | Enhancing the anti-tumor immunity elicited by alpha radiation-based brachytherapy using immunoadjuvants and blockade of suppressor cells | Vered Domankevich-Bachar, DR; Adi Cohen; Margalit Efrati; Michael Schmidt; Hans Georg Rammensee; Itzhak Kelson; Yona Keisari | Immune adjuvant; MDSC; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; TLR; Tumor microenvironment; Vaccine |
| P454 | Elucidating the functional role of type-1 interferon signaling following a medium-dose intermittent cyclophosphamide schedule in preclinical breast cancer models | Kshama Doshi, PhD; Cameron Vergato; Darren Roblyer, PhD; David J. Waxman, PhD | Chemokine; Chemotherapy; Cytokine; Gene expression; Solid tumors |
| P455 | Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of tumors and ICOS agonism in combination with radiation results in enhanced tumor control | Michael J. Gough, PhD; Shelly Bambina; Monica Gostissa, PhD; Christopher Harvey, PhD; David J. Friedman, PhD; Marka R. Crittenden, MD, PhD | Biomarkers; Checkpoint blockade; Costimulation; Radiotherapy; T cell; Tumor microenvironment |
| P456 | Pressure-enabled delivery of CAR-T cells into the porcine pancreas results in highly-targeted pancreatic delivery with minimal systemic exposure and no pancreatitis or severe systemic cytokine release | John C. Hardaway, MD, PhD; James E. Chomas, PhD; David Jaroch, PhD; Prajna Guha, PhD; N. Joseph Espat, MD, FACS; Steven C. Katz, MD; Aravind Arepally, MD | CAR T cells; Solid tumors; T cell; Targeted therapy |
| P457 | TP53 gene therapy emanating from the investigational agent SGT-53 is capable of augmenting cancer immunotherapy in multiple murine syngeneic tumor models | Joe B. Harford, PhD; Sang-Soo Kim, PhD; Kathleen F. Pirollo, PhD; Antonina Rait, PhD; Manish Moghe; Esther H. Chang, PhD | Checkpoint blockade; Gene expression; Immune tolerance; Immune toxicity; MDSC; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P458 | Contribution of an immune system to RACPP mediated drug delivery | Dina V. Hingorani, PhD; Maria F. Camargo; Matthew K. Doan, B.S.; Joesph Aguilera; Stephen R. Adams; Sunil J. Advani; | Monocyte/Macrophage; Radiotherapy; Solid tumors; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P459 | Detection of tumor-specific antibodies and their binding regions in mice cured from B78 melanoma | Anna Hoefges, MS; Amy K. Erbe, PhD; Drew Melby; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Claire Baniel, BS, BA; Clinton M. Heinze, BS; Irene M. Ong, PhD; Sean Mcilwain, PhD; Hanying Li, PhD; Richard Pinapati, PhD; Bradley H. Garcia, II, PhD; Jigar Patel, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD | Adoptive immunotherapy; Antibody; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Pediatric tumors; Proteomics; Radiotherapy; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P460 | Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer | Madhuri Koti, DVM, MVSc, PhD; Sarah Nersesian, MSc; Nichole Peterson, MSc; Julie-Ann Francis; | Chemokine; Chemotherapy; Cytokine; Gene expression; Immune adjuvant; Inflammation; Tumor microenvironment |
| P462 | Fractionated radiation with PD-1 blockade promotes anti-tumor activity in mouse head and neck cancer | Go Inokuchi, MD, PhD; Elizabeth McMichael, PhD; Masahiro Kikuchi, MD, PhD; David A. Clump, MD PhD; Robert Ferris | Checkpoint blockade; Radiotherapy; Tumor infiltrating lymphocytes (TILs) |
| P463 | HfO2 nanoparticles exposed to radiotherapy generate abscopal effect through activation of CD8+ T cells. | Audrey Darmon, BS; Ping Zhang, MD, PhD; Sébastien Paris, PhD | Immune monitoring; Monocyte/Macrophage; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P464 | Molecular targeted radiotherapy (MTRT) enhances the efficacy of immunotherapy increasing complete response rates of both local and distant disease in a “cold” tumor models | Ravi Patel, MD, PhD; Reinier Hernandez, PhD; Peter M. Carlson; Ryan Brown; Abigail Jaquish; Luke Zangl; Raghava N. Sriramaneni, PhD; Joseph Grudzinski, PhD; Bryan Bednarz, PhD; Jamey Weichert, PhD; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; | Checkpoint blockade; Cytokine; Radiotherapy; Targeted therapy |
| P465 | Comparison of peripheral immune response during chemoradiotherapy (CRT) with and without PD-1 blockade in patients with head and neck squamous cell carcinoma (HNSCC) | Juan L. Callejas-Valera, PhD; Daniel Vermeer; Christopher T. Lucido; Caitlin Williamson; Marisela Killian; William C. Spanos, MD; Paola Vermeer, PhD; Steven F. Powell, MD; | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; MDSC; Radiotherapy; T cell |
| P466 | TGF beta blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies. | Maria E. Rodriguez-Ruiz, MD, PhD; Inmaculada Rodriguez; Lina Mayorga; Tania Labiano; benigno Barbes; inaki etxeberria; Mariano Ponz-Sarvise; arantza Azpilicueta; elisabeth Bolanos; Miguel F.Sanmamed; Pedro Berraondo; Felipe Manuel Alfonso Calvo; Mary Helen Barcelos-Hoff; Jose Luis Perez-Gracia; Ignacio Melero, MD, PhD; | Antibody; Immune suppression; Radiotherapy |
| P467 | Augmenting immunity with IAP antagonists in PDAC | Kevin Roehle, PhD; Michael Dougan, MD, PhD; Stephanie K. Dougan, PhD | Checkpoint blockade; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs) |
| P468 | Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod | Mariya Rozenblit, MD; Wouter R. Hendrickx, PhD; Adriana Heguy; Luis Chiriboga; Cynthia Loomis; Karina Ray; Farbod Darvishian, MD; Mikala Egeblad, PhD; Davide Bedognetti, MD, PhD; Sylvia Adams, MD; | Chemokine; Cytokine; Gene expression; Granulocyte; Inflammation; Monocyte/Macrophage; NK/NK T cell; T cell; TLR; Tumor microenvironment |
| P469 | TCR repertoire correlates of response in tumor-bearing mice treated with radiotherapy and CTLA-4 blockade | Nils-Petter Rudqvist, PhD; Claire Lhuillier, PhD; Erik Wennerberg, PhD; Jennifer S. Sims, PhD; Sandra Demaria, MD; | Bioinformatics; Checkpoint blockade; Neoantigens; Radiotherapy; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P470 | Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer | Triparna Sen, PhD; Triparna Sen, PhD; Bertha Leticia Rodriguez; Limo Chen, PhD; Naoto Morikawa; Junya Fujimoto; Lixia Diao; Youhong Fan; Jing Wang; Bonnie S. Glisson; Ignacio Wistuba, MD; Julien Sage; John V. Heymach; Don Gibbons, MD; Lauren A. Byers, MD | Checkpoint blockade; Coinhibition; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P471 | Mertk is a therapeutic target in combination with radiation to promote adaptive immune tumor responses | Garth Tormoen, MD, PhD; Jason R. Baird, PhD; Gwen F. Kramer, BS; Shelly Bambina; Marka R. Crittenden, MD, PhD; Michael J. Gough, PhD | Monocyte/Macrophage; Radiotherapy; Solid tumors |
| P472 | Immunogenic tumor antigen is required in antitumor effect of cisplatin monotherapy and its combination with anti-PD-L1 | Daiko Wakita, PhD; Toshiki Iwai, BS; Masamichi Sugimoto, PhD; Osamu Kondoh | Checkpoint blockade; Chemotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P473 | Enhancing abscopal responses to radiation therapy by manipulating autophagy | Takahiro Yamazaki, PhD; Marissa Rybstein; Aitziber Buqué, PhD; Ai Sato; Lorenzo Galluzzi, PhD; | Checkpoint blockade; Immune adjuvant; Metabolism; Radiotherapy; Solid tumors; Systems biology |
| P474 | Antibody targeting of WNT signaling modulator dickkopf1 (DKK1) enhances innate anti-tumor immunity and complements anti-PD-1 therapy | Mike Haas; Heidi Heather; Franziska Schürpf-Huber; Lane Newman; Walter Newman, PhD; Mike Kagey; Min Yang, Ph.D.; | Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P475 | Avadomide in combination with nivolumab results in increased activated and memory T-cells and enhances CD8+ tumor infiltration in hepatocellular carcinoma patients | Patrick Hagner, PhD; Fadi Towfic, PhD; Alfredo Romano, MD; Julien Edeline, MD; Carlos Gomez-Martin, MD, PhD; Antoine Hollebecque, MD; Robin Kate Kelley, MD; Armando Santoro, MD, PhD; Michael Pourdehnad, MD; Anita Gandhi, PhD | Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Leukemia/Lymphoma; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
